🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 19 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 20/07/2001 | 42,70 | 44,36 | 42,15 | 44,02 | +2,13% | 5,18% | 1.333.800 |
| 19/07/2001 | 40,25 | 43,15 | 40,25 | 43,10 | +8,40% | 7,20% | 1.890.300 |
| 18/07/2001 | 38,23 | 40,71 | 37,85 | 39,76 | +0,63% | 7,48% | 758.400 |
| 17/07/2001 | 39,31 | 40,70 | 37,93 | 39,51 | -0,28% | 7,05% | 1.240.100 |
| 16/07/2001 | 41,50 | 42,07 | 39,20 | 39,62 | -5,06% | 6,92% | 769.000 |
| 13/07/2001 | 40,24 | 42,77 | 40,10 | 41,73 | +4,06% | 6,64% | 540.900 |
| 12/07/2001 | 40,30 | 40,45 | 38,90 | 40,10 | +1,52% | 3,85% | 1.104.600 |
| 11/07/2001 | 40,53 | 40,57 | 38,70 | 39,50 | -3,68% | 4,61% | 1.104.100 |
| 10/07/2001 | 44,30 | 45,00 | 40,76 | 41,01 | -6,82% | 9,57% | 1.731.500 |
| 09/07/2001 | 44,52 | 47,10 | 43,30 | 44,01 | -1,43% | 8,54% | 724.100 |
| 06/07/2001 | 44,61 | 45,30 | 42,77 | 44,65 | -1,93% | 5,67% | 855.200 |
| 05/07/2001 | 48,31 | 48,38 | 45,50 | 45,53 | -6,28% | 5,96% | 413.600 |
| 03/07/2001 | 46,19 | 48,85 | 46,00 | 48,58 | +3,63% | 6,17% | 482.200 |
| 02/07/2001 | 48,98 | 49,38 | 46,59 | 46,88 | -5,29% | 5,70% | 491.500 |
| 29/06/2001 | 47,61 | 49,50 | 46,56 | 49,50 | +4,34% | 6,18% | 512.000 |
| 28/06/2001 | 45,75 | 48,00 | 45,60 | 47,44 | +5,05% | 5,25% | 1.028.300 |
| 27/06/2001 | 43,71 | 45,28 | 43,21 | 45,16 | +4,54% | 4,74% | 730.500 |
| 26/06/2001 | 41,40 | 44,40 | 40,61 | 43,20 | +1,93% | 9,15% | 775.600 |
| 25/06/2001 | 45,27 | 46,22 | 41,80 | 42,38 | -5,88% | 9,76% | 1.009.100 |
| 22/06/2001 | 46,06 | 46,60 | 43,79 | 45,03 | -2,11% | 6,10% | 722.600 |
| 21/06/2001 | 46,65 | 47,14 | 45,30 | 46,00 | -1,27% | 3,94% | 570.500 |
| 20/06/2001 | 43,32 | 46,66 | 42,80 | 46,59 | +5,89% | 8,91% | 1.103.700 |
| 19/06/2001 | 45,53 | 46,71 | 43,77 | 44,00 | +0,00% | 6,46% | 576.900 |
| 18/06/2001 | 45,74 | 47,35 | 43,80 | 44,00 | -3,15% | 7,76% | 725.600 |
| 15/06/2001 | 43,25 | 46,50 | 43,25 | 45,43 | +2,97% | 7,51% | 1.160.000 |
| 14/06/2001 | 44,84 | 45,19 | 43,64 | 44,12 | -2,04% | 3,46% | 1.133.400 |
| 13/06/2001 | 46,14 | 47,71 | 44,86 | 45,04 | +0,00% | 6,18% | 689.400 |
| 12/06/2001 | 43,90 | 45,94 | 42,53 | 45,04 | -1,79% | 7,77% | 1.853.500 |
| 11/06/2001 | 48,31 | 48,40 | 45,08 | 45,86 | -5,05% | 6,87% | 851.100 |
| 08/06/2001 | 49,00 | 49,75 | 48,00 | 48,30 | -0,82% | 3,57% | 673.300 |